Aurobindo Pharma’s Eugia Unit I Gets US FDA Warning Letter; No Impact on Supplies

said Unit I of its wholly-owned subsidiary Eugia Pharma Specialities has received a warning letter from the US FDA. The unit, which contributes about 2% to the company’s overall group revenue, was earlier classified as Official Action Indicated (OAI). The company clarified there is no impact on existing supplies to the US markets and remains committed to working closely with the regulator to enhance compliance. Top stocks in the pharmaceuticals industry: Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla.